Structure Therapeutics Inc. American Depositary Shares logo

GPCRStructure Therapeutics Inc. American Depositary Shares

NASDAQ · Healthcare · Biotechnology

$47.08

-$0.05 (-0.11%)

Structure Therapeutics Inc. American Depositary Shares (GPCR) is a biotechnology company listed on NASDAQ. It is led by Raymond C. Stevens Ph.D., based in 601 Gateway Boulevard, South San Francisco, CA, United States, 94080, with about 183 employees. Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in preclinical trial to treat obesity; ANPA-0073, an oral small molecule agonist targeting the apelin, which is phase 2 ready for selective weight loss or muscle-sparing weight loss; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Net income was -$174.2M. GPCR currently screens at market cap $1.09B.

Use this GPCR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the GPCR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the GPCR SEC filings page. Lician reads the product cache first so this HTML stays unique to Structure Therapeutics Inc. American Depositary Shares even when a live quote feed is slow.

About Structure Therapeutics Inc. American Depositary Shares

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in preclinical trial to treat obesity; ANPA-0073, an oral small molecule agonist targeting the apelin, which is phase 2 ready for selective weight loss or muscle-sparing weight loss; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

GPCR Key Statistics

Market Cap

$1.09B

Volume

813,307

Previous Close

$49.92

Day Range

$48.45$50.06

00

EPS

-$0.78

Revenue

$0.00

Net Income

-$122.53M

Gross Profit

$0.00

Free Cash Flow

$0.00

Employees

183

GPCR Financials

Annual income statement in USD. Latest reported periods first.

GPCR annual income statement across FY2024, FY2023, FY2022
LineFY2024FY2023FY2022
Revenue$0.00$0.00$0.00
Cost of Revenue$0.00$0.00$0.00
Gross Profit$0.00$0.00$0.00
Operating Income$0.00$0.00$0.00
Net Income-$122.53M-$89.62M-$51.32M
EPS (Diluted)-$0.78-$0.81-$5.51

Total Assets

$903.33M

Total Debt

$0.00

Shareholders' Equity

$0.00

Cash & Equivalents

$169.51M

Operating Cash Flow

-$116.64M

Free Cash Flow

$0.00

Structure Therapeutics Inc. American Depositary Shares Company Information

CEO & Director
Raymond C. Stevens Ph.D.
Headquarters
601 Gateway Boulevard, South San Francisco, CA, United States, 94080
Phone
650 457 1978
IPO / Founded
2023-02-03
Industry
Biotechnology
Data Updated:

Upcoming Events for GPCR